| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/24/2006 | WO2006089114A2 Methods and compositions for treating an anthrax toxin mediated condition |
| 08/24/2006 | WO2006089064A1 Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody |
| 08/24/2006 | WO2006089043A2 Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis |
| 08/24/2006 | WO2006088997A2 Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin |
| 08/24/2006 | WO2006088956A2 Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
| 08/24/2006 | WO2006088890A2 Treating stroke |
| 08/24/2006 | WO2006088833A2 Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
| 08/24/2006 | WO2006088803A2 Polypeptides from staphylococcus aureus and methods of use |
| 08/24/2006 | WO2006088597A2 A plasmodium vivax hybrid circumsporozoite protein and vaccine |
| 08/24/2006 | WO2006088503A1 Delivery of enzymes to the brain |
| 08/24/2006 | WO2006088481A2 Genetically engineered equine influenza virus and uses thereof |
| 08/24/2006 | WO2006088464A2 A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| 08/24/2006 | WO2006088447A1 An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
| 08/24/2006 | WO2006088219A1 Il-13 production inhibitor |
| 08/24/2006 | WO2006087756A2 Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity |
| 08/24/2006 | WO2006087637A2 Anti her2/neu antibody |
| 08/24/2006 | WO2006087576A1 Listeriolysin-containing bacillus spores as antigen delivery agents |
| 08/24/2006 | WO2006087373A1 Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions |
| 08/24/2006 | WO2006087205A1 Live attenuated rotavirus vaccine for oral administration |
| 08/24/2006 | WO2006067635A3 USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT |
| 08/24/2006 | WO2006065746A3 Methods of treating ige-mediated disorders comprising the administration of high concentration anti-ige antibody formulations |
| 08/24/2006 | WO2006060797A3 Mri guided photodynamic therapy for cancer |
| 08/24/2006 | WO2006060419A3 Biomarkers for pre-selection of patients for anti-igf1r therapy |
| 08/24/2006 | WO2006056823A8 Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1 |
| 08/24/2006 | WO2006055638A3 Fully human monoclonal antibodies to il-13 |
| 08/24/2006 | WO2006055347A3 Desacyl ghrelin antibodies and therapeutic uses thereof |
| 08/24/2006 | WO2006050729A3 Method of preventive treatment of allergy by mucosal administration of an allergy vaccine |
| 08/24/2006 | WO2006050394A3 Combination approaches for generating immune responses |
| 08/24/2006 | WO2006042027A3 Immunogenic and therapeutic compositions for streptococcus pyogenes |
| 08/24/2006 | WO2006039327A3 Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve |
| 08/24/2006 | WO2006024954A3 Domains and epitopes of meningococcal protein nmb1870 |
| 08/24/2006 | WO2005120571A3 Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| 08/24/2006 | WO2005109991A8 Anti-theileriosis vaccine |
| 08/24/2006 | WO2005074460A9 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods |
| 08/24/2006 | WO2005051973A3 Peptides derived from natural cytotoxicity receptors and methods of use thereof |
| 08/24/2006 | WO2005030134A3 Relationship of a specific metabolite to insulin resistance |
| 08/24/2006 | WO2004033641A3 Gene expression profiling of bladder cancer |
| 08/24/2006 | US20060191024 Method for preparing anti-MIF antibodies |
| 08/24/2006 | US20060190226 Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| 08/24/2006 | US20060189794 Ligand having agonistic activity to mutated receptor |
| 08/24/2006 | US20060189792 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 08/24/2006 | US20060189791 Recombinant expression of streptococcus pyogenes cysteine protease and immunogenic compositions thereof |
| 08/24/2006 | US20060189630 Mitotic kinesin inhibitors |
| 08/24/2006 | US20060189554 Nanoparticle-Based vaccine delivery system containing adjuvant |
| 08/24/2006 | US20060189550 Immunostimulatory, Covalently lipidated oligonucleotides |
| 08/24/2006 | US20060189540 Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue |
| 08/24/2006 | US20060189538 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 08/24/2006 | US20060189521 Human Liver Regeneration Associated Protein and the Use Thereof |
| 08/24/2006 | US20060189518 Preventing/remedies for cancer |
| 08/24/2006 | US20060188991 Flexible vaccine assembly and vaccine delivery platform |
| 08/24/2006 | US20060188990 Novel prostate tumor-specific promoter |
| 08/24/2006 | US20060188925 polynucleotides that encoding a cytotoxic T-lymphocyte associated protien-4 (CTLA-4) receptor, used as vaccines |
| 08/24/2006 | US20060188923 Novel human parvovirus B19 receptor and uses thereof |
| 08/24/2006 | US20060188913 Methods and products for enhancing immune responses using imidazoquinoline compounds |
| 08/24/2006 | US20060188884 for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection; define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of |
| 08/24/2006 | US20060188872 Novel post-transcriptional regulatory elements and uses thereof |
| 08/24/2006 | US20060188527 Methods for vaccinating against malaria |
| 08/24/2006 | US20060188526 Method for enhancing the immune response to Staphylococcus aureus infection |
| 08/24/2006 | US20060188525 Relieving spastic muscle pain; ultrasonic frequency disruption of stratum corneum and applying patch containing neurotoxin |
| 08/24/2006 | US20060188524 Canine vaccine for protection against ehrlichiosis |
| 08/24/2006 | US20060188523 Methods for diagnosing and treating chronic tonsillitis |
| 08/24/2006 | US20060188522 Viral agents |
| 08/24/2006 | US20060188521 Disrupting sex steroid signal to thymus: bone marrow or hematopoietic cells |
| 08/24/2006 | US20060188520 Producing immune response eliciting human dendritic cells by contacting with isolated encoding nucleic acid |
| 08/24/2006 | US20060188519 Peptides, antibodies, and methods for the diagnosis of SARS |
| 08/24/2006 | US20060188518 Glycoconjugate vaccines for use in immune-compromised populations |
| 08/24/2006 | US20060188517 Mycobacterial sulfation pathway proteins and methods of use thereof |
| 08/24/2006 | US20060188516 Chlamydia trachomatis antigens |
| 08/24/2006 | US20060188515 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 08/24/2006 | US20060188514 Products specific to pathogenic strains and their use as vaccines and in immunotherapy |
| 08/24/2006 | US20060188513 Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians |
| 08/24/2006 | US20060188512 Active immunization to generate antibodies to solble a-beta |
| 08/24/2006 | US20060188511 Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes |
| 08/24/2006 | US20060188510 Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3 |
| 08/24/2006 | US20060188509 Extending time to disease progression or survival in cancer patients |
| 08/24/2006 | US20060188508 Methods and compositions for modulating angiogenesis |
| 08/24/2006 | US20060188507 Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors |
| 08/24/2006 | US20060188506 Therapy-enhancing glucan |
| 08/24/2006 | US20060188505 Treatment of autism |
| 08/24/2006 | US20060188504 Interleukin-13 as a cardiovascular disease marker |
| 08/24/2006 | US20060188503 Modulation of eNOS activity and therapeutic uses thereof |
| 08/24/2006 | US20060188502 Nucleic acid encoding a chimeric, humanized or CDR-grafted antibody that binds and inhibits the activity of human IL-6 |
| 08/24/2006 | US20060188501 Diagnostic and therapeutic agents for rheumatoid arthritis |
| 08/24/2006 | US20060188500 Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists |
| 08/24/2006 | US20060188499 Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| 08/24/2006 | US20060188498 Methods of using death receptor agonists and EGFR inhibitors |
| 08/24/2006 | US20060188497 Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity |
| 08/24/2006 | US20060188496 Intranasal administration of active agents to the central nervous system |
| 08/24/2006 | US20060188495 Treatment method |
| 08/24/2006 | US20060188494 Method for treating established spontaneous auto-immune diseases in mammals |
| 08/24/2006 | US20060188493 Use of an active substance that binds to cd28 for producing a pharmaceutical composition |
| 08/24/2006 | US20060188490 Transfection of blood cells with mRNA for immune stimulation and gene therapy |
| 08/24/2006 | US20060188485 Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations |
| 08/24/2006 | US20060188484 Virus vectors and methods of making and administering the same |
| 08/24/2006 | US20060188483 Virus vectors and methods of making and administering the same |
| 08/24/2006 | US20060188473 Compositions and methods for repressing B cell autoantibody secretion and for treating autoimmune disorders |
| 08/24/2006 | US20060188469 Based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants; for delivery of compositions that bind to major histocompatibility complexes (MHC) alleles |
| 08/24/2006 | US20060188446 T-cell epitope peptides |
| 08/24/2006 | US20060188440 Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer |
| 08/24/2006 | DE4192786B4 Masernvirus-Rekombinanter Pockenvirus-Impfstoff Measles virus recombinant poxvirus vaccine |